

Publikationen 2015 - 2019

Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N Engl J Med.* 2020 Jan;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. PubMed PMID:31851795.

Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, Hasler P, Rubbert-Roth A, **Schulze-Koops H**, Kempis JV. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. *J Clin Med.* 2019 Sep 26;8(10). pii: E1548. doi: 10.3390/jcm8101548. PubMed PMID: 31561582; PubMed Central PMCID: PMC6832556.

Maurus S, Sommer NN, Kooijman H, Coppentrath E, Witt M, **Schulze-Koops H**, Czihal M, Hoffmann U, Saam T, Treitl KM. 3D black-blood 3T-MRI for the diagnosis of abdominal large vessel vasculitis. *Eur Radiol.* 2020 Feb;30(2):1041-1044. doi:10.1007/s00330-019-06432-0. Epub 2019 Sep 16. PubMed PMID: 31529250.

Leipe J, Pirronello F, Klose A, **Schulze-Koops H**, **Skapenko A**. Increased plasticity of non-classic Th1 cells toward the Th17 phenotype. *Mod Rheumatol.* 2019 Oct 17:1-7. doi: 10.1080/14397595.2019.1667473. [Epub ahead of print] PubMed PMID: 31512538.

Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, Fisher BA, Hernández-Molina G, Guilpain P, Pundole X, Flores-Chávez A, Baldini C, Bingham III CO, Brito-Zerón P, Gottenberg JE, Kostine M, Radstake TRD, Schaeferbeke T, **Schulze-Koops H**, Calabrese L, Khamashta MA, Mariette X; ICIR. Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). *Clin Exp Rheumatol.* 2019 May-Jun;37 Suppl 118(3):114-122. Epub 2019 Aug 28. PubMed PMID: 31464670.

Feist J, **Murray A**, **Skapenko A**, **Schulze-Koops H**. A Rare Side Effect of Checkpoint Inhibitor Therapy-Nivolumab-Induced Axial Polyarthritits of the Facet and Costovertebral Joints. *Arthritis Rheumatol.* 2019 Nov;71(11):1823. doi: 10.1002/art.41036. Epub 2019 Sep 20. PubMed PMID: 31297971.

Czihal M, Tschaidse J, Bernau C, Lottspeich C, Köhler A, **Dechant C**, **Schulze-Koops H**, Hoffmann U, Mackert MJ, Thureau S. Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment. *Clin Exp Rheumatol.* 2019 Mar-Apr;37 Suppl 117(2):61-64. Epub 2019 May 21. PubMed PMID: 31162028.

Jaworski J, Matucci-Cerinic M, **Schulze-Koops H**, Buch MH, Kucharz EJ, Allanore Y, Kavanaugh A, Young P, Babic G. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. *Arthritis Res Ther.* 2019 May 28;21(1):130. doi: 10.1186/s13075-019-1907-x. PubMed PMID:31138316; PubMed Central PMCID: PMC6540397.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSICIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. *N Engl J Med.* 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. PubMed PMID:31112379.

Dörner T, **Schulze-Koops H**, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). *Clin Exp Rheumatol.* 2019 Nov Dec;37(6):937-945. Epub 2019 Apr 16. PubMed PMID: 31025930.

Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, **Schulze-Koops H**. Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA. *Clin Exp Rheumatol.* 2019 Sep-Oct;37(5):783-790. Epub 2019 Apr 9. PubMed PMID: 30963994.

Moog P, Valda K, Eren OE, Rauschel V, Kossegg SJ, Bachmann Q, Schmaderer C, Straube A, **Schulze-Koops H**, Witt M. A complex pattern of autonomic dysfunction in familial Mediterranean fever. Results from a controlled cross-sectional study. *Clin Exp Rheumatol.* 2019 Nov-Dec;37 Suppl 121(6):35-42. Epub 2019 Mar 18. PubMed PMID: 30943130.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, **Schulze-Koops H**, Schett G, Spiera R, Unizony SH, Collinson N. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. *Arthritis Rheumatol.* 2019 Aug;71(8):1329-1338. doi: 10.1002/art.40876. Epub 2019 Jul 3. PubMed PMID: 30835950; PubMed Central PMCID: PMC6772126.

Mueller RB, Spaeth M, von Restorff C, Ackermann C, **Schulze-Koops H**, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. *J Clin Med.* 2019 Mar 3;8(3). pii: E302. doi: 10.3390/jcm8030302. PubMed PMID: 30832414; PubMed Central PMCID:PMC6462919.

Lottspeich C, **Dechant C**, Köhler A, Tischler M, Treitl KM, Treitl M, **Schulze-Koops H**, Hoffmann U, Czihal M. Assessment of Disease Activity in Takayasu Arteritis: Potential Role of Contrast-Enhanced Ultrasound. *Ultraschall Med.* 2019 Oct;40(5):638-645. doi: 10.1055/a-0817-5423. Epub 2019 Jan 23. PubMed PMID:30674040.

Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, Foeldvari I, Föll D, Frosch M, Ganser G, Gaubitz M, Günther A, Heinz C, Horneff G, Huemer C, Kopp I, Lommatzsch C, Lutz T, Michels H, Neß T, Neudorf U, Pleyer U, Schneider M, **Schulze-Koops H**, Thureau S, Zierhut M, Lehmann HW. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. *Semin Arthritis Rheum.* 2019 Aug;49(1):43-55. doi: 10.1016/j.semarthrit.2018.11.004. Epub 2018 Dec 4. Review. PubMed PMID: 30595409.

Publikationen 2015 - 2019

Schramm N, Ingenhoff J, **Dechant C**, Treitl KM, Treitl M, Proft F, **Schulze-Koops H**, Hoffmann U, Bartenstein P, Rominger A, Czihal M. Diagnostic accuracy of positron emission tomography for assessment of disease activity in large vessel vasculitis. *Int J Rheum Dis*. 2019 Aug;22(8):1371-1377. doi:10.1111/1756-185X.13440. Epub 2018 Nov 22. PubMed PMID: 30565885.

Tony HP, Krüger K, Cohen SB, **Schulze-Koops H**, Kivitz AJ, Jeka S, Vereckei E, Cen L, Kring L, Kollins D. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2019 Jan;71(1):88-94. doi:10.1002/acr.23771. PubMed PMID: 30295429.

Möhnle P, Pekrul I, Spannagl M, **Sturm A, Singh D, Dechant C**. Emicizumab in the Treatment of Acquired Haemophilia: A Case Report. *Transfus Med Hemother*. 2019 Apr;46(2):121-123. doi: 10.1159/000497287. Epub 2019 Mar 15. PubMed PMID: 31191199; PubMed Central PMCID: PMC6514512.

Bley T, Zänker M, **Dechant C**, Venhoff N. [Current Recommendations for Diagnostics in Giant Cell Arteritis]. *Dtsch Med Wochenschr*. 2019 May;144(9):587-594. doi: 10.1055/a-0831-0812. Epub 2019 Apr 26. German. PubMed PMID: 31026867.

Delgado GE, Krämer BK, Siekmeier R, Yazdani B, März W, **Leipe J**, Kleber ME. Influence of smoking and smoking cessation on biomarkers of endothelial function and their association with mortality. *Atherosclerosis*. 2020 Jan;292:52-59. doi:10.1016/j.atherosclerosis.2019.11.017. Epub 2019 Nov 15. PubMed PMID: 31783198.

Choy EHS, Miceli-Richard C, González-Gay MA, Sinigaglia L, Schlichting DE, Meszaros G, de la Torre I, **Schulze-Koops H**. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. *Clin Exp Rheumatol*. 2019 Jul-Aug;37(4):694-704. Epub 2019 Feb 11. Review. PubMed PMID: 30767864.

Dechant C, Schulze-Koops H. [Update Giant Cell Arteritis]. *Dtsch Med Wochenschr*. 2019 Oct;144(20):1432-1436. doi: 10.1055/a-0722-6620. Epub 2019 Oct 8. Review. German. PubMed PMID: 31594019.

Leipe J, Mariette X. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. *Rheumatology (Oxford)*. 2019 Dec 1;58(Suppl 7):vii49-vii58. doi: 10.1093/rheumatology/kez360. Review. PubMed PMID: 31816078; PubMed Central PMCID: PMC6900914.

Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, **Leipe J**, Pauschinger M, Vogel A, Zimmer L, Gutzmer R. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. *ESMO Open*. 2019 May 23;4(3):e000491. doi: 10.1136/esmoopen-2019-000491. eCollection 2019. Review. PubMed PMID: 31231568; PubMed Central PMCID: PMC6555610.

Knünz A, Schulze-Koops H. [Morbus Bechterew - diagnosis and therapy]. *MMW Fortschr Med*. 2019 Mar;161(Suppl 1):61-69. doi: 10.1007/s15006-019-0013-y. Review. German. PubMed PMID: 30912085.

J. Leipe and H. Schulze-Koops. 2018. [Paraneoplastic syndromes in rheumatology]. *Internist* 59:145-50, epub 16 Jan 2018

C. Gabay, B. Fautrel, J. Rech, F. Spertini, E. Feist, I. Kötter, E. Hachulla, J. Morel, T. Schaeferbeke, M.A. Hamidou, T. Martin, B. Hellmich, P. Lamprecht, **H. Schulze-Koops**, D.S. Courvoisier, A. Sleight, and E.J. Schiffrin. 2018. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. *Ann Rheum Dis* 77:840-7, epub 22 Feb 2018

K. Heinemann, J. v. Kempis, R. Sauter, T. Sokka-Isler, **H. Schulze-Koops**, M. Schiff, and R. Müller. 2018. Long-term increase of radiographic damage and disability in patients with RA in relation to disease duration in the era of biologics. Results from the SCQM cohort. *J Clin Med* 7(3). pii: E57. doi: 10.3390/jcm7030057, epub 13 Mar 2018

T. Häupl, **A. Skapenko**, B. Hoppe, K. Skriner, H. Burkhardt, D. Poddubnyy, S. Ohrndorf, P. Sewerin, U. Mansmann, B. Stuhl Müller, **H. Schulze-Koops**, and G.-R. Burmester. 2018. [Biomarkers and imaging for diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the BMBF consortium ArthroMark]. *Z Rheumatol* 77(S1):16-23, epub 24 Apr 2018

R.B. Mueller, T. Kaegi, S.R. Haile, **H. Schulze-Koops**, M. Schiff, and J. von Kempis. 2018. Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. *RMD Open* 2018;4:e000673. doi:10.1136/rmdopen-2018-000673, epub 06 Jun 2018

C. Fiehn, J. Holle, C. Iking-Konert, **J. Leipe**, C. Weseloh, M. Frerix, R. Alten, F. Behrens, C. Baerwald, J. Braun, H. Burkhardt, G. Burmester, J. Detert, M. Gaubitz, A. Gause, E. Gromnica-Ihle, H. Kellner, A. Krause, J. Kuipers, H.M. Lorenz, U. Müller-Ladner, M. Nothacker, H. Nüsslein, A. Rubbert-Roth, M. Schneider, **H. Schulze-Koops**, S. Seitz, H. Sitter, C. Specker, H.P. Tony, S. Wassenberg, J. Wollenhaupt, and K. Krüger. 2018. [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. *Z Rheumatol* 77 (S2):25-53, epub 03 Jul 2018

R.B. Mueller*, M. Gruenke*, J. Wendler, F. Schuch, K. Hofmann-Preiß, I. Boettger, R. Jakobs, **H. Schulze-Koops**, and J. v. Kempis. 2018. The value of an automated ultrasound system in the detection of synovitis. *Ultrasound Int Open* 4:E61-8, epub 11 Jul 2018

T.A. Stamm, K.P. Machold, D. Aletaha, F. Alasti, P. Lipsky, D. Pisetsky, R. Landewe, D. van der Heijde, A. Sepriano, M. Aringer, D. Boumpas, G. Burmester, M. Cutolo, W. Ebner, W. Graninger, T. Huizinga, G. Schett, **H. Schulze-Koops**, P.P. Tak, E. Martin-Mola, F. Breedveld, and J. Smolen. 2018. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. *Arthritis Res Ther* 20:174, epub 09 Aug 2018

Publikationen 2015 - 2019

- J. Leipe**, L. Christ, A. Arnoldi, E. Mille, F. Berger, M. Heppt, L. Goldschneider, E. Diego, R. M. Huber, **C. Dechant**, C. Berking, **H. Schulze-Koops**, and **A. Skapenko**. 2018. Characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy. *RMD Open* 4:e000714, epub 17 Aug 2018
- M. Aringer and **H. Schulze-Koops**. 2018. [Immunology of systemic inflammatory diseases]. *Orthopade*, epub 28 Sep 2018
- H.P. Tony, K. Krüger, S. Cohen, **H. Schulze-Koops**, A. Kivitz, S. Jeka, E. Vereckei, L. Cen, L. Kring, and D. Kollins. 2018. Safety and immunogenicity of rituximab biosimilar GP2013 after switch from reference rituximab in patients with active rheumatoid arthritis. *Arthritis Care Res*, epub 08 Oct 2018
- M. Matucci-Cerinic, Y. Allanore, A. Kavanaugh, M. Buch, H. Schulze-Koops, E.J. Kucharz, H. Woehling, G. Babic, J. Poetzl, A. Schwebig, and A. Davis. 2018. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared to the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative Phase III, randomised, double-blind, EQUIRA study. *RMD Open*, in press
- A. Skapenko**, J. Smolen, A. Kavanaugh, V. Arora, H. Kupper, and **H. Schulze-Koops**. 2018. Genetic Markers Are Associated With Clinical and Radiographic Response in Patients With Rheumatoid Arthritis Who Received Adalimumab Plus Methotrexate Combination Therapy or Methotrexate Monotherapy in the OPTIMA Study. *Clin Exp Rheumatol*, in press
- N. Schramm, J. Ingenhoff, C. Dechant, K.-M. Treitl, M. Treitl, F. Proft, **H. Schulze-Koops**, U. Hoffmann, P. Bartenstein, A. Rominger, and M. Czihal. 2018. Diagnostic accuracy of positron emission tomography for assessment of disease activity in large vessel vasculitis. *Int J Rheum Dis*, in press
- R.E. Voll, P. Lamprecht, K. Warnatz, **H. Schulze-Koops**, H.-H. Peter, and W.J. Pichler. 2017. [Immunsystem]. In: *Klinische Pathophysiologie*, edited by H.U. Blum and D. Müller-Wieland. Thieme, Stuttgart, 10th. Edition, Chapter 16 pp 559-648
- Curtis JR, **Schulze-Koops H**, Takiya L, Mebus CA, Terry KK, Biswas P, and Jones TV. 2017. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. *Clin Exp Rheumatol*, epub 04 Jan 2017
- Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüsslein, Reuss-Borst M, Schwarting A, **Schulze-Koops H**, Tausche AK, and Braun J. 2017. [Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector: S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF]. *Z Rheumatol* 76:118-24, epub 11 Jan 2017
- Schulze-Koops H**, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, and Wang L. 2017. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. *Rheumatology* 56:46-57
- Ledderose GJ, **Schulze-Koops H**, and Link V. 2017. [A Blocked Frontal Sinus with Orbital Swelling]. *Laryngorhinotologie* 96:180-2
- Czihal M, Schrötle A, Baustel K, Lottspeich C, **Dechant C**, Treitl KM, Treitl M, **Schulze-Koops H**, and Hoffmann U. 2017. B-mode sonography wall thickness assessment of the temporal and axillary arteries for the diagnosis of giant cell arteritis: a cohort study. *Clin Exp Rheumatol* 35(S103):128-33, epub 04 Apr 2017
- Skapenko A**, **Schulze-Koops H**. 2017. Defining epigenetic regulation of IL9 gene by chromatin immunoprecipitation. *Methods Mol Med* 1585:179-87
- Proft F, Czihal M, Rémi J, Fesl G and **Schulze-Koops H**. 2017. Fatal spontaneous bilateral vertebral artery dissection in giant cell arteritis (GCA). *J Vasc* 3:2
- Stone JH, Tuckwell K, Dimonaco S, Klearman M, Mallalieu NL, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, **Schulze-Koops H**, Schett G, Spiera R, Unizony SH and N. Collinson. 2017. Tocilizumab for Remission in Giant Cell Arteritis. *New Engl J Med* 377:317-28
- Moog P, Eren O, Kossegg S, Valda K, Straube A, Grünke M, **Schulze-Koops H**, Witt M. 2017. Pupillary autonomic dysfunction in patients with ANCA-associated vasculitis. *Clin Auton Res* 27:385-92, epub 01 Sep 2017
- Venhoff N, Proft F, **Schulze-Koops H**, Holle J, Voll RE, Iking-Konert C, Jacobi AM, Henes J, Unger L, Kneitz O, Dörner T, Thiel J. 2018. [Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis: Efficacy and safety analysis of a national registry (GRAID2)]. *Z Rheumatol* 77:21-7, epub 15 May 2017
- Henes JC, **Schulze-Koops H**, Witt M, Tony HP, Mueller F, Grunke M, Czihal M, Dörner T, Proft F. 2018. [Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica: Safety and efficacy analysis of a nationwide German registry (GRAID2)]. *Z Rheumatol* 77:12-20, epub 23 May 2017
- Fiehn C, Unger L, **Schulze-Koops H**, Proft F, Henes JC, Jacobi A, Dörner T. 2018. [Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry]. *Z Rheumatol* 77:40-5, epub 23 May 2017
- Proft F, M. Fleck, Fiehn C, **Schulze-Koops H**, Witt M, Dörner T, and Henes JC. 2018. [Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases: Experiences from a German registry (GRAID2)]. *Z Rheumatol* 77:46-54, epub 06 Jun 2017
- Proft F, **Schulze-Koops H**, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler, Behrens

Publikationen 2015 - 2019

- F, Burmester GR, and Dörner T. 2018. [Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy: Data from a nationwide German registry (GRAID2)]. *Z. Rheumatol* 77_28-39, epub 06 Jun 2017
- Czihal M, Lottspeich C, Schröttle A, Treitl KN, **Leipe J**, **Schulze-Koops H**, Hoffmann U, and **Dechant**. 2018. Relapses in three patients with Takayasu arteritis under tocilizumab treatment detected by contrast enhanced ultrasound. *Vasa* 47:149-52, epub Dec 2017
- Braun J, Lorenz HM, Müller-Ladner U, Schneider M, **Schulze-Koops H**, Specker C, Strangfeld A, Wagner U, and Dörner T. 2018. Revised version of the statement by the DGRh on biosimilars – update 2017. *Z Rheumatol* 77: 81-90
- Sewerin P, Klein S, Brinks R, Hoyer A, Schleich C, Miese F, Blaschke S, Edelmann E, Gao I, Georgi J, Kellner H, Keyßer G, Lorenz HM, Müller-Ladner U, Pott HG, **Schulze-Koops H**, Walther M, Schneider M, and Ostendorf B. 2017. [REMISSIONPLUS eine Initiative zur Integration moderner Bildgebung in die rheumatologische Versorgung Rückblick, Einblick, Ausblick: Auswertung der Niederfeld-MRT Daten]. *Aktuelle Rheumatologie*
- Hassel JC, Heinzerling L, Aberle J, et al. (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. *Cancer Treat Rev* 57:36-49 2016
- Milger K, Yu Y, Brudy E, Irmeler M, **Skapenko A**, Mayinger M, Lehmann M, Beckers J, Reichenberger F, Behr J, Eickelberg O, Königshoff M, Krauss-Etschmann S. Pulmonary CCR2+CD4+ T cells are immune regulatory and attenuate lung fibrosis development. *Thorax*. 2017 Nov;72 (11):1007-1020
- Wakefield D, McCluskey P, Wildner G, Thurau S, Carr G, Chee SP, Forrester J, Dick A, Hudson B, Lightman S, Smith J, Tugal-Tutkun I; pre-treatment assessment Review panel. 2017. Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. *Autoimmun Rev* 16:213-22, epub 27 Jan 2017
- Edwards CJ, Fautrel B, **Schulze-Koops H**, Huizinga TW, Kruger K. 2017. Dosing down with biologic therapies: a systematic review and clinician's perspective. *Rheumatology* 35:390-400, epub 16 Feb 2017
- Feist E, **Schulze-Koops H**, Rubbert-Roth A, Witte T. [Januskinase-Inhibition mit Olumiant® (Baricitinib). Ein neuer Weg in der Therapie der rheumatoiden Arthritis]. *Thieme Praxis Report* 9(7):1-12, 2017
- Schulze-Koops H** [Zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA]. *Thieme Praxis Report* 9(8):1-12, 2017
- Leipe J** and **Schulze-Koops H**, Pathogenetic concepts of joint diseases. In: Pietschmann P (ed) Principles of bone and joint research. Springer, Cham, pp 173–187, 2017
- Schulze-Koops H**. Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases. *Rheumatology* 56(S4):iv1-3, epub 01 Aug 2017
- Schulze-Koops H** and **Skapenko A**. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. *Rheumatology* 56(S4): iv30-48, pub 01 Aug 2017
- Kalden JR and **Schulze-Koops H**. Immunogenicity and loss of response to TNF inhibitors: impact on rheumatoid arthritis treatment. *Nature Rev Rheumatol* 13: 707-18, epub 21 Nov 2017
- Voll RE, Lamprecht P, Warnatz K, **Schulze-Koops H**, Peter HH, Pichler WJ. [Immunsystem]. In: Klinische Pathophysiologie, edited by W. Siegenthaler and H.U. Blum. Thieme Verlag, Stuttgart, 10th. Edition, Chapter 20, 2017
- Vastesaegeer N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, Wollenhaupt J, Zerbin CA, Louw I, Combe B, Beaulieu A, **Schulze-Koops H**, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, Durez P. 2016. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. *Rheumatology* 55:1466-76, epub 25 April 2016
- Braun J, Krause A, Aringer M, Burmester G, Bessler F, Engel JM, Faubel U, Fischer-Betz R, Genth E, Gromnica-Ihle E, Hellmich B, Kötter I, Krüger K, Lakomek J, Lorenz HM, Manger B, Märker-Hermann E, Minden K, Müller-Ladner U, Rautenstrauch J, Rehart S, Riemekasten G, Rudwaleit M, Rütger W, Schett G, Schuch F, **Schulze-Koops H**, Specker C, Wassenberg S, Wiek D, Zink A, Schneider M. 2016. [Standards of care for people with rheumatoid arthritis in Europe: Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"]. *Z Rheumatol* 75:416-28, epub 02 May 2016
- Riemekasten G, Aringer M, Baerwald CG, Meyer-Bahblurg A, Bergner A, Feuchtenberger M, **Gebhardt C**, Hellmich B, Keyßer G, Lorenz HM, Kneitz C, Witte T, Müller-Ladner U, Schneider M, Braun J, Rautenstrauch J, Specker C, **Schulze-Koops H**. 2016. [Rheumatology - Integration into student training (RISA): Current structure of clinical rheumatology in German universities (RISA III)]. *Z Rheumatol* 75:493-501, epub 19 May 2016
- Proft F, Grunke M, Reindl C, Mueller F, Kriegmair M, **Leipe J**, Weinert P, **Schulze-Koops H**, Witt M, "The Influence of Long Distance Running on Sonographic Joint and Tendon Pathology: Results from a Prospective Study with Marathon Runners", *BMC Musculoskelet Disord* 2016, 17 (1): 272
- Witt M, Frielinghausen J, Mueller RB, Mueller F, Proft F, **Schulze-Koops H**, Grunke M, Clevert A, "Evaluation of a Novel Semi-Automated Ultrasound System for the Detection of Synovitis: A Prospective Study involving 45 Patients with Rheumatoid Arthritis", *Ultrasound Int Open* 2016, 2 (4): E117-E123

Publikationen 2015 - 2019

- Sturm A, **Dechant C**, Proft F, **Schulze-Koops H**, Hoffmann U, Czihal M. 2016. Gender differences in giant cell arteritis: a case-control study. *Clin Exp Rheumatol* 34 S97:70-2, epub 24 Mar 2016
- Moog P, Eren O, Witt M, Rauschel V, Kossegg S, Straube A; Grunke M, **Schulze-Koops H**, "Assessment of autonomic function in a cohort of patients with ANCA-associated vasculitis", *Clin Auton Res* 2016, 26 (4): 279
- Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüßlein H, Reuss-Borst M, Schwarting A, **Schulze-Koops H**, Tausche A, Braun J. 2016. [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. *Z Rheumatol* 75S2:11-60, epub 01 Aug 2016
- Treitl KM, Maurus S, Sommer NN, Kooijman-Kurfuerst H, Coppentrath E, Treitl M, Czihal M, Hoffmann U, **Dechant C**, **Schulze-Koops H**, Saam T. 2016. 3D-black-blood 3T-MRI for the diagnosis of thoracic large vessel vasculitis: A feasibility study. *Eur Radiol*, epub 10 Aug 2016
- Mueller RB, Reshiti N, Kaegi T, Finkh A, Haile SR, **Schulze-Koops H**, Schiff M, Spaeth M, Kempis J. 2016. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). *Clin Rheumatol* 36:59-66, epub 12 Nov 2016
- F. Heldmann, X. Baraliakos, U. Kiltz, J. Brandt, I.E. van der Horst-Bruinsma, R. Landewé, J. Sieper, G.R. Burmester, F. van den Bosch, K. de Vlam, H. Gaston, M. Gruenke, **M. Witt**, T. Appelboom, P. Emery, M. Dougados, M. Leirisalo-Repo, M. Breban, J. Braun, "Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety", *Clin Exp Rheumatol* 2016, 34 (2): 184
- Hohlfeld R and **Schulze-Koops H**. 2016. Cytotoxic T cells going awry in inclusion body myositis. *Brain*, 139:1312-4, epub 25 April 2016
- Witt M **Schulze-Koops H**. 2016. [Hyperuricemia and gout: New aspects of an old disease]. *Der Internist* 57:656-65, epub 10 Jun 2016
- Sander O, **Dechant C**, Sunderkötter C, Klein-Weigel P, Kapillarmikroskopie, Nailfold Capillary Microscopy, Georg Thieme Verlag. (IF 0.069)
- Schulze-Koops H**, Giacomelli R, Samborski W, Rednic S, Herold M, Yao R, Govoni M, Vastesaegeer N, and Weng HH. 2015. Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. *Clin Exp Rheumatol* 33:201-8, epub 29 Jan 2015
- Czihal M, Piller A, Schroettle A, Kuhlenkordt P, Bernau C, **Schulze-Koops H**, and Hoffmann U. 2015. Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. *J Vasc Surg* 61.1285-91, epub 03 Feb 2015
- A. Radbruch, **H. Schulze-Koops**. 2015. From cellular pathology to cell therapy. *Z Rheumatol*. 2015 Feb;74(1):6-7
- P. Moog, H. Schulze-Koops**, K. Thürmel. 2015. Comment on: Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. *Rheumatology (Oxford)*. 2015 Feb;54(2):372-3
- J. Leipe**. Interleukin-22-friend or foe? *Z Rheumatol*. 2015 Feb; 74(1):51-3. doi:10.1007/s00393-013-1331-6
- J. Leipe**, H.D. Chang. Effector T cells. *Z Rheumatol*. 2015 Feb; 74(1):14-9. doi:10.1007/s00393-014-1441-9
- S. Haupt, V. Söntgerath, J. Leipe, H. Schulze-Koops, A. Skapenko**. Methylation of an intragenic alternative promoter regulates transcription of GARP. *Biochim Biophys Acta*. 2015 Nov 14;1859(2):223-234.
- Rommer P S, Dörner T, Freivogel K, Haas J, Kieseier B C, Kümpfel T, Paul F, Proft F, **Schulze-Koops H**, Schmidt E, Wiendl H, Ziemann U, Zettl U K and GRAID investigators. 2016. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). *Neuroimmune Pharmacology*, epub 20 Nov 2015
- T. Witte and **H. Schulze-Koops**. 2015. IgG4-related sialadenitis: IgG4 is helpful, but biopsies are still crucial. *Arthritis Res Ther* 17:368, epub 18 Dec 2015
- K. Standfest, M. Englbrecht, K. Krueger, W. Ochs, M. Schmitt-Haendle, H. Kellner, H.P. Tony, S. Kleinert, M. Feuchtenberger, F. Schuch, J. Wendler, **H. Schulze-Koops**, M. Grünke, M. Witt, M. Fleck, J. Zwerina, K. Manger, B. Manger, G. Schett, A.J. Hueber and J. Rech. 2015. Effects of concomitant conventional and previous biological disease modifying anti-rheumatic drugs treatment on the efficacy of tocilizumab to induce remission in patients with rheumatoid arthritis – an observational real-life study. *Rheumatology (Sunnyvale)* 5:157-64
- Henkemeier, Alten, Bannert B, Baraliakos X, Behrens F, Heldmann F, Kiltz U, Khm M, König R, **Leipe J**, Müller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, **Schulze-Koops H**, Specker C, Tausche AK, Wassenberg S, **Witt M**, Zernicke J, Burkhardt H. Do we still need clinical studies in rheumatology?. *Z Rheumatol*. 2015 Dec 19 (epub ahead of print)
- RB. Mueller, M. Schiff, T. Kaegi, A. Finckh, SR. Haile, **H. Schulze-Koops**, J. von Kempis, Swiss Clinical Quality Management (SCQM) physicians. 2015. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. *Clin. Rheumatol*. 2015 Jan; 34 (1):51-9, epub 2014 Jul 15
- G.R. Burmester, P. Durez, G. Shestakova, M.C. Genovese, **H. Schulze-Koops**, Y. Li, A. Wang, S. Lewitzky, I. Koroleva, A. Agarwal, D.M. Lee, W. Hueber, for the Secukinumab in RA Biomarker Study Group. 2015. Association of *HLA-DRB1* Alleles with Clinical Responses to the Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Active Rheumatoid Arthritis. *Rheumatology*, pii: kev258, epub 12 Aug 2015

Publikationen 2015 - 2019

P. Venalis, G. Kumánovics, **H. Schulze-Koops**, A. Distler, C. Dees, P. Zerr, K. Palumbo-Zerr, L. Czirják, Z. Mackevic, IE. Lundberg, O. Distler, G. Schett, JH. Distler. 2015. Cardiomyopathy in murine models of systemic sclerosis. *Arthritis Rheumatol.* 2015 Feb;67 (2):508-16

E. Schuh, P. Lohse, B. Ertl-Wagner, **M. Witt**, M. Krumbholz, M. Frankenberger, L.A. Gerdes, R. Hohlfeld, T. Kümpfel, "Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations", *Neurol Neuroimmunol Neuroinflamm* 2015, 2 (4): e109

N. Nirmala, A. Brachat, E. Feist, N. Blank, C. Specker, **M. Witt**, J. Zernicke, A. Martini A, G. Junge, "Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity", *Pediatr Rheumatol Online J* 2015, 20 (13): 50